hVIVO plc HVO

hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the company's results for the first half of 2026, its record order book, full-year guidance and the expansion of its clinical research services. Khan said hVIVO generated around £16.3 million in revenue in H1, alongside an EBITDA loss of £4.5 million, ending the period with £13 million in cash, a performance in line with the company's previous guidance that 2026 would be weighted towards the second half. A key focus was the order book. Three sizeable human challenge trial contracts, including hVIVO

Chesnara PLC (LSE:CSN) saw operating capital generation jump 79% to £96 million in the first half.  CEO Steve Murray also highlighted the group's 185% solvency coverage ratio and an active acquisition pipeline. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to push forward its CNS drug pipeline.  That includes trials for alcohol use disorder and addiction treatments. hVIVO PLC (AIM:HVO) has bought CRS Berlin to expand into dermatology and women's health trials.  The CEO says it opens up new markets and cross-selling opportunities in Germany. Gelion PLC (AIM:GELN, OTC:G

hVIVO PLC (AIM:HVO) has bought a Berlin clinical research unit for just €250,000 upfront. Most of the price is tied to future revenue, keeping the deal self-funding. Rome Resources Plc (AIM:RMR) has returned strong tin and tungsten results from its New Brunswick exploration in Canada. Trenching starts in September, with a possible drill campaign lined up for 2027. Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) called Q2 its "best quarter yet," with adjusted EBITDA up 300% year on year. Revenue more than doubled thanks to growth in Colombia's Tapir block. Bradda Head Lithium Ltd (AIM:BH